Solid Biosciences Inc.
SLDBNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for SLDB. That does not mean none is planned.
Get an email about SLDB's next catalysts
Track Solid Biosciences (SLDB) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 1 past
No catalysts found.
Market Overview
Stock performance and key metrics
SGT-003
Duchenne Muscular Dystrophy
trofosfamide, idarubicin, etoposide
Soft Tissue Sarcoma
genexolPM + cisplatin
Locally Advanced Head and Neck Squamous Cell Carcinoma
Cetuximab
Head and Neck Neoplasm
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
SGT-003 | Phase 3 | Duchenne Muscular Dystrophy | - | - |
trofosfamide, idarubicin, etoposide | Phase 3 | Soft Tissue Sarcoma | - | - |
genexolPM + cisplatin | Phase 2 | Locally Advanced Head and Neck Squamous Cell Carcinoma | - | - |
Cetuximab | Phase 2 | Head and Neck Neoplasm | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Solid Biosciences Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Solid Biosciences Inc.'s (SLDB) pipeline across Phase 3, Phase 2. Its lead program is SGT-003 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Solid Biosciences Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Solid Biosciences Inc. (SLDB) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track SLDB biotech catalysts?→
Add SLDB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Solid Biosciences Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.